Davide Bonazzi
Illustrator
From this contributor
Company on brink takes psilocybin to trial for fragile X syndrome
The phase 2A trial has its detractors despite positive animal results and is being sponsored by a company that is struggling financially.
Company on brink takes psilocybin to trial for fragile X syndrome
Explore more from The Transmitter
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.
‘Friction-maxxing’ in school: Students should read primary literature, not AI summaries
Trainees need to learn how to identify a neuroscience paper’s major takeaways and integrate them into their understanding. This skill doesn’t come from outsourcing the work to large language models.
‘Friction-maxxing’ in school: Students should read primary literature, not AI summaries
Trainees need to learn how to identify a neuroscience paper’s major takeaways and integrate them into their understanding. This skill doesn’t come from outsourcing the work to large language models.